Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma Cmn (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 29,885
  • Shares Outstanding, K 22,470
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,060 K
  • 36-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.30 +2.31%
on 05/15/17
1.47 -9.52%
on 04/27/17
-0.12 (-8.28%)
since 04/26/17
3-Month
1.11 +19.82%
on 03/03/17
2.76 -51.81%
on 03/10/17
+0.11 (+9.02%)
since 02/24/17
52-Week
1.08 +23.15%
on 02/01/17
7.89 -83.14%
on 09/29/16
-5.61 (-80.84%)
since 05/26/16

Most Recent Stories

More News
J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021

Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.

CATB : 1.33 (-2.21%)
VVUS : 1.13 (+0.89%)
JNJ : 126.92 (-0.48%)
PFE : 32.14 (-0.06%)
Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth

On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.

OREX : 2.97 (+1.02%)
CATB : 1.33 (-2.21%)
VVUS : 1.13 (+0.89%)
EPZM : 15.60 (-3.41%)
Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress

-- MoveDMD Trial Progressing, Part C Interim Results Expected in Q3 2017 --

CATB : 1.33 (-2.21%)
Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 11, 2017 / Catabasis Pharmaceuticals Inc (NASDAQ: CATB) will be discussing their earnings results in their Q1 Earnings Call to be held May 11, 2017 at 4:30 PM Eastern Time....

CATB : 1.33 (-2.21%)
Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde

Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss...

ENZ : 9.08 (+0.33%)
CATB : 1.33 (-2.21%)
SHPG : 177.18 (-4.13%)
MACK : 3.30 (-2.94%)
Technical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma

Stock-Callers.com has initiated coverage on Celsion Corp. (NASDAQ: CLSN), Incyte Corp. (NASDAQ: INCY), ImmunoGen Inc. (NASDAQ: IMGN), and Catabasis Pharmaceuticals Inc. (NASDAQ: CATB). Biotechnology firms...

CATB : 1.33 (-2.21%)
INCY : 134.38 (-2.91%)
IMGN : 4.72 (-6.90%)
CLSN : 0.23 (-4.17%)
Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y

Orexigen Therapeutics, Inc.'s (OREX) loss of $4.67 per share in the first quarter of 2017 was significantly wider than the Zacks Consensus Estimate of a loss of $2.60 and the year-ago loss of $1.54.

ENZ : 9.08 (+0.33%)
OREX : 2.97 (+1.02%)
CATB : 1.33 (-2.21%)
AGTC : 5.35 (-1.83%)
Arena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down

Arena Pharmaceuticals, Inc. (ARNA) reported loss of 9 cents per share in the first quarter of 2017, same as in the year-ago period but wider than the Zacks Consensus Estimate of a loss of 8 cents.

CATB : 1.33 (-2.21%)
AXON : 21.73 (+0.09%)
ARNA : 1.31 (-3.68%)
AGTC : 5.35 (-1.83%)
Catabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD(R) Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting

-- Part C Interim Results to be Announced in Q3 2017 --

CATB : 1.33 (-2.21%)
Catabasis Pharmaceuticals to Present at the American Academy of Neurology 69th Annual Meeting

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from Part A and Part B of the MoveDMD trial of...

CATB : 1.33 (-2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Support & Resistance

2nd Resistance Point 1.37
1st Resistance Point 1.35
Last Price 1.33
1st Support Level 1.32
2nd Support Level 1.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.